Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Bemnifosbuvir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025

    07 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3075940/0/en/Atea-Pharmaceuticals-Announces-Full-Results-from-Phase-2-Study-of-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-HCV-Presented-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    07 May 2025
    Share Share
    Atea Pharmaceuticals to Host Virtual HCV Panel on May 14, 2025
    Atea Pharmaceuticals to Host Virtual HCV Panel on May 14, 2025

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072229/0/en/Atea-Pharmaceuticals-to-Host-Virtual-HCV-KOL-Panel-on-May-14-2025.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share
    Atea Pharmaceuticals to Present Best-in-Class Hepatitis C Regimen
    Atea Pharmaceuticals to Present Best-in-Class Hepatitis C Regimen

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066217/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Showcasing-Potential-Best-in-Class-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Atea Pharmaceuticals Starts Phase 3 Study on Hepatitis C Virus
    Atea Pharmaceuticals Starts Phase 3 Study on Hepatitis C Virus

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058258/0/en/Atea-Pharmaceuticals-Announces-Dosing-of-First-Patient-in-C-BEYOND-Phase-3-Study-Evaluating-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share
    Atea Pharma To Present Bemnifosbuvir Preclinical Data At ICAR
    Atea Pharma To Present Bemnifosbuvir Preclinical Data At ICAR

    19 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/19/3045224/0/en/Atea-Pharmaceuticals-Announces-Presentation-of-Bemnifosbuvir-Preclinical-Data-at-the-38th-International-Conference-on-Antiviral-Research-ICAR-2025.html

    GLOBENEWSWIRE
    19 Mar 2025
    Share Share
    Atea Pharma Announces Positive Ph 2 Results for HCV Regimen
    Atea Pharma Announces Positive Ph 2 Results for HCV Regimen

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991333/0/en/Atea-Pharmaceuticals-Announces-Positive-Results-from-Phase-2-Study-of-Bemnifosbuvir-and-Ruzasvir-Regimen-for-Treatment-of-Hepatitis-C-Virus-HCV.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share